- Home
- NTRB vs CMRX Comparison
NTRB vs CMRX Comparison
Compare NTRB & CMRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NTRB
- CMRX
- Stock Information
- Founded
- NTRB 2016
- CMRX 2000
- Country
- NTRB United States
- CMRX United States
- Employees
- NTRB N/A
- CMRX N/A
- Industry
- NTRB Industrial Specialties
- CMRX Biotechnology: Pharmaceutical Preparations
- Sector
- NTRB Health Care
- CMRX Health Care
- Exchange
- NTRB Nasdaq
- CMRX Nasdaq
- Market Cap
- NTRB 77.9M
- CMRX 77.0M
- IPO Year
- NTRB N/A
- CMRX 2013
- Fundamental
- Price
- NTRB $6.17
- CMRX $0.93
- Analyst Decision
- NTRB
- CMRX Strong Buy
- Analyst Count
- NTRB 0
- CMRX 1
- Target Price
- NTRB N/A
- CMRX $11.00
- AVG Volume (30 Days)
- NTRB 28.2K
- CMRX 119.4K
- Earning Date
- NTRB 12-11-2024
- CMRX 11-08-2024
- Dividend Yield
- NTRB N/A
- CMRX N/A
- EPS Growth
- NTRB N/A
- CMRX N/A
- EPS
- NTRB N/A
- CMRX N/A
- Revenue
- NTRB $1,803,816.00
- CMRX $144,000.00
- Revenue This Year
- NTRB N/A
- CMRX $3,040.12
- Revenue Next Year
- NTRB N/A
- CMRX N/A
- P/E Ratio
- NTRB N/A
- CMRX N/A
- Revenue Growth
- NTRB N/A
- CMRX N/A
- 52 Week Low
- NTRB $1.93
- CMRX $0.75
- 52 Week High
- NTRB $9.60
- CMRX $1.30
- Technical
- Relative Strength Index (RSI)
- NTRB 50.57
- CMRX 60.78
- Support Level
- NTRB $5.24
- CMRX $0.80
- Resistance Level
- NTRB $6.40
- CMRX $0.98
- Average True Range (ATR)
- NTRB 0.71
- CMRX 0.05
- MACD
- NTRB -0.12
- CMRX 0.01
- Stochastic Oscillator
- NTRB 33.23
- CMRX 83.33
About NTRB Nutriband Inc.
Nutriband Inc is engaged in the development of a portfolio of transdermal pharmaceutical products. AVERSA technology is the company's lead product that incorporates aversive agents to prevent the Abuse, Diversion, Misuse, and Accidental exposure of drugs with abuse potential specifically Opioids. The majority of the revenue is generated from the sale of goods that include consumer transdermal and coated products.
About CMRX Chimerix Inc.
Chimerix Inc. is a biopharmaceutical company based in the United States that engages in the research, development, and commercialization of medicines. Its portfolio includes treatment for acute myeloid leukemia (or AML) and antiviral treatment for smallpox. The company generates revenue through revenue related to non-refundable upfront fees, royalties and milestone payments earned under license agreements, also by royalty revenue related to sales of TEMBEXA made by Emergent after the Asset Sale. The company operates only in one business segment namely pharmaceuticals.